Youth with gender dysphoria, also known as transgender youth, are increasingly presenting to multidisciplinary clinics within academic pediatric centers across the United States. Gender-affirming pharmacological interventions for adolescents with gender dysphoria may be used to promote positive psychological well-being and mental health outcomes. Interventions range from completely reversible to partially irreversible, based on the age and sexual maturity of the adolescent. For each intervention, dilemmas and controversies exist regarding age at treatment initiation, treatment duration, safety, and cost. Pharmacists’ awareness of these considerations and interventions is important when providing evidence-based gender-affirming care to this underserved population.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Washington, DC: American Psychiatric Association; 2013.
2.
VanceSREhrensaftDRosenthalSM.Psychological and medical care of gender nonconforming youth. Pediatrics. 2014;134:1184-1192. doi:10.1542/peds.2014-0772
3.
HembreeWCCohen-KettenisPDelemarre-vandeWaalHA. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:3132-3154. doi:10.1210/jc.2009-0345
4.
ColemanEBocktingWBotzerM. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend. 2012;13:165-232.
5.
SpackNPEdwards-LeeperLFeldmanHA. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics. 2012;129:418-425. doi:10.1542/peds.2011-0907
6.
WoodHSasakiSBradleySJ. Patterns of referral to a gender identity service for children and adolescents (1976-2011): age, sex ratio, and sexual orientation. J Sex Marital Ther. 2013;39:1-6. doi:10.1080/0092623X.2012.675022
7.
ChenMFuquaJEugsterEA.Characteristics of referrals for gender dysphoria over a 13-year period. J Adolesc Health. 2016;58:369-371. doi:10.1016/j.jadohealth.2015.11.010
8.
VanceSRHalpern-FelsherBLRosenthalSM.Health care providers’ comfort with and barriers to care of transgender youth. J Adolesc Health. 2015;56:251-253. doi:10.1016/j.jadohealth.2014.11.002
9.
SteensmaTDKreukelsBPde VriesALCohen-KettenisPT.Gender identity development in adolescence. Horm Behav. 2013;64:288-297. doi:10.1016/j.yhbeh.2013.02.020
10.
MilrodCKarasicDH.Age is just a number: WPATH-affiliated surgeons’ experiences and attitudes toward vaginoplasty in transgender females under 18 years of age in the United States. J Sex Med. 2017;14:624-634. doi:10.1016/j.jsxm.2017.02.007
11.
OlsonKRDurwoodLDeMeulesMMcLaughlinKA.Mental health of transgender children who are supported in their identities. Pediatrics. 2016;137:e20153223. doi:10.1542/peds.2015-3223
12.
OlsonJSchragerSMBelzerMSimonsLKClarkLF.Baseline physiologic and psychosocial characteristics of transgender youth seeking care for gender dysphoria. J Adolesc Health. 2015;57:374-380. doi:10.1016/j.jadohealth.2015.04.027
13.
NahataLQuinnGPCaltabellottaNMTishelmanAC.Mental health concerns and insurance denials among transgender adolescents. LGBT Health. 2017;4:188-193. doi:10.1089/lgbt.2016.0151
14.
KattariSKHascheL.Differences across age groups in transgender and gender non-conforming people’s experiences of health care discrimination, harassment, and victimization. J Aging Health. 2016;28:285-306. doi:10.1177/0898264315590228
15.
StapinskiLABowesLWolkeD. Peer victimization during adolescence and risk for anxiety disorders in adulthood: a prospective cohort study. Depress Anxiety. 2014;31:574-582. doi:10.1002/da.22270
16.
RussellSTRyanCToomeyRBDiazRMSanchezJ.Lesbian, gay, bisexual, and transgender adolescent school victimization: implications for young adult health and adjustment. J Sch Health. 2011;81:223-230. doi:10.1111/j.1746-1561.2011.00583.x
17.
FuquaJS.Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98:2198-2207. doi:10.1210/jc.2013-1024
18.
de VriesALSteensmaTDDoreleijersTACohen-KettenisPT.Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med. 2011;8:2276-2283. doi:10.1111/j.1743-6109.2010.01943.x
19.
de VriesALMcGuireJKSteensmaTDWagenaarECDoreleijersTACohen-KettenisPT.Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014;134:696-704. doi:10.1542/peds.2013-2958
20.
VlotMCKlinkDTden HeijerMBlankensteinMARotteveelJHeijboerAC.Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone. 2017;95:11-19. doi:10.1016/j.bone.2016.11.008
21.
KlinkDCarisMHeijboerAvan TrotsenburgMRotteveelJ.Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab. 2015;100:E270-E275. doi:10.1210/jc.2014-2439
22.
GieddJN.The teen brain: insights from neuroimaging. J Adolesc Health. 2008;42:335-343. doi:10.1016/j.jadohealth.2008.01.007
23.
StevensJGomez-LoboVPine-TwaddellE.Insurance coverage of puberty blocker therapies for transgender youth. Pediatrics. 2015;136:1029-1031. doi:10.1542/peds.2015-2849
24.
Edwards-LeeperLSpackNP.Psychological evaluation and medical treatment of transgender youth in an interdisciplinary “Gender Management Service” (GeMS) in a major pediatric center. J Homosex. 2012;59:321-336. doi:10.1080/00918369.2012.653302
25.
MensahFKBayerJKWakeMCarlinJBAllenNBPattonGC.Early puberty and childhood social and behavioral adjustment. J Adolesc Health. 2013;53:118-124. doi:10.1016/j.jadohealth.2012.12.018
26.
SchoelwerMJDonahueKLBrykKDidrickPBerenbaumSAEugsterEA.Psychological assessment of mothers and their daughters at the time of diagnosis of precocious puberty. Int J Pediatr Endocrinol. 2015;2015:5. doi:10.1186/s13633-015-0001-7
27.
ReisnerSLVettersRLeclercM. Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study. J Adolesc Health. 2015;56:274-279. doi:10.1016/j.jadohealth.2014.10.264
28.
ChrislerJCGormanJAManionJ. Queer periods: attitudes toward and experiences with menstruation in the masculine of centre and transgender community. Cult Health Sex. 2016;18:1238-1250. doi:10.1080/13691058.2016.1182645
29.
AltshulerALHillardPJ.Menstrual suppression for adolescents. Curr Opin Obstet Gynecol. 2014;26:323-331. doi:10.1097/GCO.0000000000000098
30.
Al-FutaisiAMAl-ZakwaniISAlmahreziAMMorrisD.Subcutaneous administration of testosterone: a pilot study report. Saudi Med J. 2006;27:1843-1846.
31.
SchwalliePCAssenzoJR.Contraceptive use: efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril. 1973;24:331-339.
32.
HidalgoMBahamondesLPerrottiMDiazJDantas-MonteiroCPettaC.Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65:129-132.
33.
MillerLHughesJP.Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653-661.
34.
KanjRVConradLETrotmanGE.Menstrual suppression and contraceptive choices in a transgender adolescent and young adult population. J Pediatr Adolesc Gynecol. 2016;29:188-210. doi:10.1016/j.jpag.2016.01.100
35.
HatcherRNelsonA.Combined hormonal contraceptive methods. In: HatcherRTrussellJStewartF, eds. Contraceptive Technology. 18th ed.New York, NY: Ardent Media Inc; 2005:226;391-451.
36.
NappiCBifulcoGTommaselliGAGarganoVDi CarloC.Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86:606-621. doi:10.1016/j.contraception.2012.04.009
37.
CorvolPMichaudAMenardJFreifeldMMahoudeauJ.Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology. 1975;97:52-58.
38.
GridleySJCrouchJMEvansY. Youth and caregiver perspectives on barriers to gender-affirming health care for transgender youth. J Adolesc Health. 2016;59:254-261. doi:10.1016/j.jadohealth.2016.03.017
39.
WeinandJDSaferJD.Hormone therapy in transgender adults is safe with provider supervision: a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol2015;2:55-60. doi:10.1016/j.jcte.2015.02.003
40.
DeutschMBBhakriVKubicekK.Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol. 2015;125:605-610. doi:10.1097/AOG.0000000000000692
41.
Ethics Committee of the American Society for Reproductive Medicine. Access to fertility services by transgender persons: an Ethics Committee opinion. Fertil Steril. 2015;104:1111-1115.
ChenDSimonsLJohnsonEKLockartBAFinlaysonC. Fertility preservation for transgender adolescents. J Adolesc Health. 2017;61(1):120-123.
44.
NilssonJJervaeusALampicC. “Will I be able to have a baby?” Results from online focus group discussions with childhood cancer survivors in Sweden. Hum Reprod. 2014;29:2704-2711. doi:10.1093/humrep/deu280
45.
SteinDMVictorsonDEChoyJT. Fertility preservation preferences and perspectives among adult male survivors of pediatric cancer and their parents. J Adolesc Young Adult Oncol. 2014;3:75-82.
46.
RichardsCBoumanWPSealLBarkerMJNiederTOT’SjoenG.Non-binary or genderqueer genders. Int Rev Psychiatry. 2016;28:95-102. doi:10.3109/09540261.2015
47.
BhasinSCunninghamGRHayesFJ. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559. doi:10.1210/jc.2009-2354
48.
PalmertMRDunkelL.Clinical practice: delayed puberty. N Engl J Med. 2012;366:443-453. doi:10.1056/NEJMcp1109290
49.
FaienzaMFBrunettiGAcquafreddaA. Metabolic outcomes, bone health, and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues. Horm Res Paediatr. 2017;87:162-169. doi:10.1159/000456546
50.
BishopBM.Pharmacotherapy considerations in the management of transgender patients: a brief review. Pharmacotherapy. 2015;35:1130-1139. doi:10.1002/phar.1668
51.
OlsonJGarofaloR.The peripubertal gender-dysphoric child: puberty suppression and treatment paradigms. Pediatr Ann. 2014;43:e132-e137. doi:10.3928/00904481-20140522-08
52.
CromerBAScholesDBerensonA. Depot medroxyprogesterone acetate and bone mineral density in adolescents: the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296-301.
53.
DayanandaID.Contraception. In: EmansSJLauferMR, eds. Pediatric and Adolescent Gynecology. 6th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2012;447-473.
